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Acute exacerbation can occur in ILDs associated with a progressive-fibrosing phenotype, other than
IPF; and are associated with significant morbidity. There are pressing needs to identify patients at risk
of AE and for therapies that reduce this risk. http://ow.ly/tEA330mNE0r
Cite this article as: Kolb M, Bondue B, Pesci A, et al. Acute exacerbations of progressive-fibrosing
interstitial lung diseases. Eur Respir Rev 2018; 27: 180071 [https://doi.org/10.1183/16000617.0071-2018].
ABSTRACT Acute exacerbation of interstitial lung disease (ILD) is associated with a poor prognosis and
high mortality. Numerous studies have documented acute exacerbation in idiopathic pulmonary fibrosis
(IPF), but less is known about these events in other ILDs that may present a progressive-fibrosing
phenotype. We propose defining acute exacerbation as an acute, clinically significant respiratory
deterioration, typically less than 1 month in duration, together with computerised tomography imaging
showing new bilateral glass opacity and/or consolidation superimposed on a background pattern consistent
with fibrosing ILDs. Drawing on observations in IPF, it is suspected that epithelial injury or proliferation
and autoimmunity are risk factors for acute exacerbation in ILDs that may present a progressive-fibrosing
phenotype, but further studies are required. Current acute exacerbation management strategies are based
on recommendations in IPF, but no randomised controlled trials of acute exacerbation management have
been performed. Although there are no formal strategies to prevent the development of acute exacerbation,
possible approaches include antifibrotic drugs (such as nintedanib and pirfenidone), and minimising
exposure to infection, airborne irritants and pollutants. This review discusses the current knowledge of
acute exacerbation of ILDs that may present a progressive-fibrosing phenotype and acknowledges
limitations of the data available.
Copyright ©ERS 2018. ERR articles are open access and distributed under the terms of the Creative Commons
Attribution Non-Commercial Licence 4.0.
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Fibrosing interstitial lung diseases (ILDs) remain a significant therapeutic and diagnostic challenge. Some
patients with fibrosing ILDs develop a progressive phenotype [1]. Progressive-fibrosing ILD (PF-ILD) is a
terminology recently used to describe these patients [1]. Idiopathic pulmonary fibrosis (IPF) may be
regarded as the prototype PF-ILD; all patients with this condition develop a progressive-fibrosing
phenotype. Progressive fibrosis occurs in other ILDs; however, unlike in IPF, it only affects a proportion of
patients [1, 2]. The clinical course and diagnosis of ILDs with a progressive-fibrosing phenotype are
discussed by COTTIN et al. [3] in this issue of European Respiratory Review. Acute exacerbation (AE) of ILDs
(AE-ILD) can occur at any point during the course of disease and is characterised by rapid respiratory
deterioration (marked increase in dyspnoea and hypoxaemia) associated with new widespread alveolar
abnormality [4–7]. The features of AE-ILD are not uniformly defined throughout the literature; however, in
most cases, AE-ILD manifests radiographically as new diffuse, bilateral, ground-glass opacification (with or
without consolidation) superimposed on a background of chronic fibrotic changes consistent with fibrosing
ILDs on high-resolution computed tomography scans [6, 7]. Histopathologically, AE-ILD most commonly
manifests as diffuse alveolar damage superimposed on a background of fibrosing ILD (e.g. usual interstitial
pneumonia), but other patterns have been described (e.g. organising pneumonia) [4, 8–13].
It is well documented that AE of IPF can be both unpredictable and often fatal, but less is known about
these events in patients with other ILDs that may present a progressive-fibrosing phenotype. This review
describes the current body of knowledge, drawing from experience in IPF where appropriate.
Impact of AEs in ILDs that may present a progressive-fibrosing phenotype
In most ILDs that may present a progressive-fibrosing phenotype, it is difficult to assess the impact of AE
as there are limited epidemiologic data on their incidence and prevalence [14]. Furthermore, the overall
incidence of AE varies widely between studies, depending on the method of analysis and disease
definitions used. The annual incidence of AE in IPF is reported to be 5–19% and is less common in
milder forms of IPF [8, 15–25]. In other ILDs where a percentage of patients develop a progressive-
fibrosing phenotype, the highest AE rates are reported in patients with a histological or radiological
pattern of usual interstitial pneumonia (UIP). This can be observed in patients with chronic
hypersensitivity pneumonitis, asbestosis, fibrosing nonspecific interstitial pneumonia (NSIP), and
connective tissue disease (CTD)-ILDs (e.g. rheumatoid arthritis-associated ILD (RA-ILD) or systemic
sclerosis-associated ILD (SSc-ILD)) [4, 6, 10, 11, 13, 26–34].
AE in IPF and other fibrosing ILDs that may present a progressive phenotype is associated with a poor
prognosis and a high rate of mortality; which in turn contributes to a high economic burden, primarily
from a high rate of hospitalisation [7, 25, 35, 36]. The post-exacerbation mortality in ILDs is reported to
range from 33–83% [6, 28]; with hospital mortality rates of 50–100% in CTD-ILDs and 75–100% in
patients with hypersensitivity pneumonitis [6, 10, 11, 13]. It is proposed that lower baseline lung function
parameters, impaired oxygenation and a higher fibrosis score/more extensive radiological disease may
increase the risk of mortality in IPF patients with an AE [23, 36–39]. In addition, the marked acceleration
in the progression of fibrosis and lung function decline, in combination with a significant worsening in
respiratory signs and symptoms (including dyspnoea and hypoxaemia), can substantially impact quality of
life and the ability of patients to carry out their activities of daily living [40].
Proposed definition of AE in ILDs that may present a progressive-fibrosing
phenotype
At present, there is not a widely accepted single definition of AE for all ILDs that may present a
progressive-fibrosing phenotype. The International Working Group defined AE in IPF as an acute
clinically signiﬁcant respiratory deterioration, typically less than 1 month in duration, and can be
categorised as extraparenchymal (e.g. pulmonary embolism, pneumothorax, pleural effusion) or
parenchymal [7, 41]. Although initially defined to be caused by unknown and unidentifiable aetiologies,
AE of IPF has now been recognised to include both idiopathic and triggered events (e.g. infection, drug
toxicity, aspiration). In line with this definition, an AE in ILDs that may present a progressive-fibrosing
phenotype is proposed to be an acute, clinically significant, respiratory deterioration characterised
radiologically by new widespread alveolar abnormality typically less than 1 month in duration.
In terms of diagnostics, patients present with acute worsening or development of dyspnoea, typically less
than 1 month in duration. Thromboembolic disease should be excluded using computed tomography (CT)
imaging with a pulmonary embolism protocol. The CT image of patients with AE should show new
bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with
fibrosing ILD (including, but not limited to the presence of a UIP pattern, honeycombing) (figure 1); and
deterioration not fully explained by cardiac failure (or fluid overload). This definition is being used in an
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ongoing, randomised, double-blind, placebo-controlled, phase III trial of nintedanib in PF-ILD (excluding
IPF) (ClinicalTrials.gov identifier: NCT02999178; INBUILD), where time to first AE or death over
52 weeks is a pre-specified key secondary end-point [1].
The diagnosis of AE-ILD relies solely on clinical and radiological findings. In patients with IPF,
bronchoscopy with bronchoalveolar lavage (BAL) had been considered necessary to exclude an infectious
aetiology, but there are findings to suggest that the outcome is similar in exacerbations with an identifiable
trigger or in idiopathic cases. There remains an argument for selective use of bronchoscopy with BAL in
certain patients, particularly those who are receiving immunosuppression at the time of presentation that
increases the risk of atypical and opportunistic infections [42, 43]. Lung biopsies have limited value, as it is
difficult to determine if pathological changes are due to acute lung injury or caused by the underlying
disease; in addition, nonelective lung biopsy in patients with ILDs is associated with a high inpatient
mortality and rarely influences treatment decisions [44–46]. While pulmonary function tests show a
progressive decline in forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide
(DLCO) in ILDs that may present a progressive-fibrosing phenotype, AEs are thought to be more likely to
show abrupt worsening in both these metrics [16, 22, 26, 47].
Risk factors associated with AE
Contrary to AE-IPF, it is uncertain whether AE in ILDs that may present a progressive-fibrosing
phenotype can be the first presentation of the disease. Based on observations in IPF, it is proposed that
epithelial injury or proliferation, coagulation abnormalities, and autoimmunity are contributing factors [7].
As described above, AE of other ILDs that may present a progressive-fibrosing phenotype is not caused by
thromboembolic disease, cardiac failure, fluid overload or an alternative noninfectious pulmonary
condition (such as pulmonary embolism, pneumothorax, or pleural effusion) [7, 17].
Data from retrospective studies in IPF suggest that AE is more commonly observed in nonsmoking,
older patients with more advanced disease (e.g. those with a low and/or recent decline in FVC, low
DLCO or those requiring supplemental oxygen) [6, 7, 23, 48–51]. However, it is important to remain
vigilant, as AE-ILD can occur in patients with well-maintained physiological and clinical status across all
ages. In many cases of AE in IPF, no external triggers are identified [7]; however, there is limited
evidence to suggest that it may be precipitated by infection, microaspiration, surgical lung biopsy,
surgical resection, bronchoscopy (BAL, cryobiopsy), air pollution, prior exacerbation events and some
medications (e.g. methotrexate or tocilizumab for RA-ILD or α-interferon) [5, 6, 10, 28, 38, 41, 52–57].
AE is also more frequently observed during the winter season, reflecting an increased rate of viral
infections [41].
Blood-based biomarkers can play an important role in predicting the clinical course and outcomes of
ILDs [58]. However, while some blood-based biomarkers of AE-ILD have been suggested (e.g. lactate
a) b) c)
FIGURE 1 A 63-year-old woman with rheumatoid arthritis-associated interstitial lung disease who presented
to clinic with 2 weeks of increasing shortness of breath. Axial and coronal images show a) baseline computed
tomography 1 year before presentation showing reticulation and honeycombing in a definite usual interstitial
pneumonia pattern; b) presentation of acute exacerbation of interstitial lung disease with new onset bilateral
ground-glass opacities on background of usual interstitial pneumonia and c) follow-up computed tomography
1 week after treatment with high-dose steroids showing some improvement in ground-glass opacification.
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dehydrogenase, C-reactive protein, Krebs von den Lungen-6, pro-calcitonin, circulating fibrocytes, elevated
interleukin-17 and anti-heat shock protein 70 autoantibodies, syndecan-4), only a limited number have been
validated in prospective studies [51, 59, 60].
Management of AE
There are no randomised studies on which to base optimal management of AE in ILDs. In IPF,
international management guidelines recommend the use of supportive care with symptom palliation and
long-term oxygen therapy (for patients with resting hypoxaemia) [17]. Beyond supportive care in IPF,
corticosteroids are prescribed, based on anecdotal evidence of benefit (particularly when organising
pneumonia is present) and the high mortality rate [4, 7, 17, 61]. In other ILDs that may present a
progressive-fibrosing phenotype, limited retrospective studies suggest that corticosteroids may confer a
benefit in AE of idiopathic interstitial pneumonia (IIP), CTD-ILDs and in selected cases of sarcoidosis and
hypersensitivity pneumonitis. However, the reported post-exacerbation mortality rates remain high and the
optimal regimen has yet to be defined [7, 11, 13, 31, 62, 63]. It is particularly important to note that
high-dose steroids should be used with caution in patients with SSc-ILD due to the associated risk of SSc
renal crisis [64, 65]. In cases of suspected AE, it is recommended to identify and eliminate potential
exposure to causative toxic agents on a case-by-case basis, particularly in cases of hypersensitivity
pneumonitis. Empiric broad-spectrum antibiotics are often administered to patients with AEs to rule out
difficult-to-identify infectious agents and antiviral therapy can be used during periods of heightened risk
(e.g. oseltamivir during the influenza season) [7]. Immunosuppressive agents (such as cyclosporine A,
cyclophosphamide, tacrolimus or azathioprine) can also be used in combination with corticosteroids, but,
while some efficacy signals have been observed in small uncontrolled studies in IPF, there is no conclusive
evidence to support their use [6, 31, 66–68].
Patients with AE of IPF may develop hypoxic respiratory failure requiring intervention with mechanical
ventilation; however, this is associated with a high mortality rate and has to be assessed on a case-by-case
basis as the risk may outweigh the benefit. For example, mechanical ventilation can be used as a bridge to
lung transplant in eligible patients [17, 69]. An alternative approach is to use nasal cannula oxygen, either
conventional or high-flow, which is suggested by a small number of studies to potentially support
breathing and avoid the need for intubation/mechanical ventilation [70–72]. Use of noninvasive ventilation
may also be considered [73, 74]. The last resort for some patients following an acute worsening of IPF is
lung transplantation, but given the nature of the disease, a minority of patients are likely to be considered
eligible [17].
The use of extracorporeal membrane oxygenation (ECMO) is emerging to become an effective
management method. ECMO has the possibility of minimising the risk of “triggering” underlying chronic
processes that can lead to fatal deterioration of the lungs by providing extracorporeal lung support, which
can allow one to reduce the invasiveness of ventilation. ECMO may also bridge the period necessary for
registering selected patients for a lung transplant [26, 75, 76].
Although the discussion here has focused on AE of IPF, the management approaches are likely to be
applicable to patients with other ILDs that may present a progressive-fibrosing phenotype. It is important
to note, however, that further controlled studies are required, as the available data are extremely limited
and although IPF is considered a prototype of other PF-ILDs, there are some differences between these
ILDs. For example, those with other PF-ILDs may be more likely to have elements of an inflammatory
process during an AE (i.e. organising pneumonia admixed with dense fibrosis) and therefore may be more
likely to benefit from acute immunomodulatory therapy than in AE-IPF.
Preventive strategies
There are no formal recommendations for the treatment of ILDs that may present a progressive-fibrosing
phenotype or the prevention of AEs. Data from studies in patients with IPF suggest that antifibrotic drugs
(such as nintedanib and pirfenidone) could have a role in preventing AE, but it is not clear whether these
agents should be withheld or continued during an exacerbation event [77].
Two phase II trials have reported contrasting results for pirfenidone as a preventive treatment for AE of
IPF, with one study showing a benefit and the other failing to demonstrate an effect [21, 78]. In a
meta-analysis of five randomised trials, pirfenidone was associated with decreases in all-cause mortality
and IPF-related mortality, but there was no significant decrease in the incidence of AEs [79]. There is
some evidence that perioperative use of pirfenidone in IPF patients may prevent post-operative
exacerbations [80, 81]. While exacerbations were not included as an end-point in phase III trials of
pirfenidone, a pooled analysis of data from the three pivotal studies showed that patients treated with
pirfenidone had a lower risk of respiratory-related hospitalisations than those in the placebo arms of these
trials [82–84].
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In a phase II study, nintedanib appeared to delay the time to first AE in patients with IPF (according to
investigator assessment), but only one of the two pivotal INPULSIS phase III trials showed a statistically
significant effect of nintedanib to reduce AE of IPF versus placebo (p=0.02) [20, 85]. In both phase III
trials, nintedanib reduced the decline in FVC, which is consistent with slowing the progression of IPF [20].
Pooled analyses of phase II and phase III data have since suggested a prolongation of the time to first AE
of IPF with nintedanib [86–88]. Nintedanib may prolong survival after an AE, but the small number of
events included in the analysis does not allow definitive conclusions [7]. Also, the delay in time to first AE
may have resulted from a delay in loss of lung function, which potentially would make these patients
statistically less likely to suffer with an AE.
Considering other ILDs, a small retrospective study has suggested that pirfenidone may reduce
inflammation in patients with an AE of interstitial pneumonia who are undergoing corticosteroid
treatment [89]. However, the drug did not improve the survival rate at 30 and 90 days compared with
untreated patients. As stated previously, the phase III INBUILD trial (ClinicalTrials.gov identifier:
NCT02999178 ) is currently investigating the efficacy of nintedanib versus placebo on outcomes including
the incidence of AEs in patients with PF-ILD [1].
Other potential preventive measures in AE of IPF and other ILDs that may present a progressive-fibrosing
phenotype may include influenza and pneumococcal vaccination, hand washing and avoidance of sick
contacts, avoidance of airborne irritants and pollutants, and strategies to minimise mechanical
ventilator-induced lung injury [59]. Despite the observation that gastro-oesophageal reflux disease may be
a potential risk factor for the progression of IPF, it is not clear whether anti-acid treatment has a
preventive effect on the development of AE of IPF and other IPF-related outcomes due to conflicting data
[87, 90]. A recent study suggests that anti-acid treatment may reduce IPF-related mortality but notes that
randomised trials are required [91]. Furthermore, anti-acid treatment may increase the risk of infection in
patients with more advanced disease [87].
Conclusions
AE of ILDs that may present a progressive-fibrosing phenotype is an unpredictable serious life-threatening
event that can occur at any time during the disease course. Data on the incidence of AE in ILDs that may
present a progressive-fibrosing phenotype is limited, but for most of these diseases the rate is thought to
be lower than that for IPF despite similarities in the clinical presentation and course. The diagnosis of AE
in ILDs that may present a progressive-fibrosing phenotype is reliant on clinical and radiological findings,
but the choice of method should be considered on a case-by-case basis. The risk factors associated with
the development of AE are poorly defined; therefore, there is a need for biomarkers to identify at-risk
patients. Treatment of AE is based on scant evidence in IPF and further studies are required to determine
the optimal approach. Although further data are required, nintedanib and pirfenidone may prove to have a
role in the prevention of AE of ILDs that may present a progressive-fibrosing phenotype.
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